Deadline Alert: Regeneron Pharmaceuticals Inc. REGN
Published on January 25, 2025
Regeneron Pharmaceuticals Inc. (REGN) is facing an important deadline, as investors who have lost money are being urged to contact Glancy Prongay Murray LLP about a securities fraud lawsuit. The lawsuit alleges that the company made false and misleading statements regarding the safety and efficacy of its flagship drug. Investors who suffered losses are recommended to seek legal counsel and potentially join the class action against Regeneron Pharmaceuticals Inc.
Investor opinions & comments
To leave a comment, you need to Login or Register.
There are no comments yet. Be the first to leave one!